Effects of a thromboxane A2 receptor antagonist in an animal model of inflammatory bowel disease

Digestion

Volumn 58, Issue 5, 1997, Pages 476-478

  Tanignchi, Takao ^a   Tsukada, Hideaki ^a   Nakamura, Hiroshi ^a   Kodama, Masanobu ^a   Fukuda, Kazuhito ^a   Tominaga, Masayuki ^b   Seino, Yutaka ^a  

^a KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Inflammatory bowel disease; Thromboxane A2 receptor antagonist; Trinitrobenzenesulfonic acid induced colitis

Indexed keywords

ONO NT 126; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BICYCLO COMPOUNDS; COLITIS; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; FATTY ACIDS, MONOUNSATURATED; LEUKOTRIENE B4; MALE; RATS; RATS, WISTAR; RECEPTORS, THROMBOXANE; THROMBOXANE A2; TRINITROBENZENESULFONIC ACID;

EID: 0030879843     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201486     Document Type: Article

References (20)

1. Zifroni A, Treves AJ, Sachar DB, Rachmilc-witz D: Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease, Gut 1983:24:659-664.
2. Lauritsen K, Laursen LS, Bukhavc K, Rask-Madsen J: In vivo profiles of cicosanoids in ulcerative colitis, Crohn’s colitis and Cl, difficile colitis, Gastroenterology 1988:95:11-17.
3. Rampton DS, Hawkey C'J: Prostanoids and ulcerative colitis, Gut 1984:25:1399-1413.
4. Rampton DS, Collins CE: Thromboxanes in inflammatory bowel disease-pathogenic and therapeutic implications, Aliment Pharmacol Ther 1993;7:357-367.
5. Vilaseca J, Salas A, Guamer F, Rodriguez R, Malagelada J: Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis, Gastroenterology 1990;98:269-277.
6. Banerjec AK, Peters TJ: Experimental non-ste-roidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors, Gut 1990;31:1358-1364.
7. Allgayer H, Dcschrvvcr K, Stenson WF: Treatment with 16,16'-dimethyl prostaglandin E2 before and after induction of colitis with trini-trobenzenesulfonic acid in rats decreases inflammation, Gastrocnterologv 1989:96:1290-1300.
8. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon, Gastroenterology 1989;96:795-803.
9. Naka M, Hamanaka N, Sugioka M, Iwamura H, Sakata M, Kira H, Okcgawa T, Kawasaki A: Pharmacological effects of a novel thromboxane A2 receptor antagonist, ONO-NT-126, Proc Biosignalling in Cardiac and Vascular Systems, 1988, pp 422-425.
10. Nakahata N, Sato K, Abe MT, Nakanishi H: ONO-NT-126 is a potent and selective thromboxane A2 antagonist in human astrocytoma cells, Eur J Pharmacol 1990:184:233-238.
11. Sharon P, Stenson WF: Metabolism of arachi-donicacid in acetic acid colitis in rats, Similarity to human inflammatory bowel disease, Gastroenterology 1985;88:55-63.
12. Boughton-Smith NK, Whittle BJR: Increased metabolism of arachidonic acid in an immune model of colitis in guinea pigs, Br J Pharmacol 1985;86:439-446.
13. Hamberg M, Svensson J, Samuclsson B: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endopcroxides, Proc Natl Acad Sci USA 1975; 72:2994-2298.
14. Wakefield AJ, Sawvcrr AM, Dhillon AP, Pittilo RM, Rowels PM, Lewis AAM, Pounder RE: Pathogenesis of Crohn’s disease: Multifocal gastrointestinal infarction, Lancet 1989;ii: 1057-1062.
15. Doukas J, Hechtman HB, Shepko D: Endothelial cell-secreted arachidonic acid metabolites modulate leukocyte chemotaxis and diapede-sis, Blood 1988:71:771-779.
16. Goldman G, Welbourn R, Valeri CR, Shapro D, Hechtman HB: Thromboxane A2 induces Icukotrienc B4 synthesis that in turn mediates neutrophil diapedesis via CD 18 activation, MicrovascRes 1991;41:367-375.
17. Fiddler GI, Lumlcy P: Preliminary clinical studies with thromboxane synthetase inhibitors and thromboxane receptor blockers, Circulation 1990;81:169-178.
18. Gresele P, Dcckmyn H, Nenci CG, Vermylen J: Thromboxane synthetase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders, Trends Pharmacol Sci 1991;12:158-163.
19. Casellas F, Papo M, Guamer F, Antolin M, Segura RM, Armcngol JR, Malagelda JR: Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis, Eur J Gastroenterol Hepatol 1995;7:221-226.
20. Collins CE, Forbes A, Rampton DS: Antiplatelet therapy in active Crohn’s disease: An open trial using picotamidc, a thromboxane antagonist (abstract), Gastroenterology 1995: 108:799.